UA88508U - Method for correcting impaired purine metabolism in patients with arterial hypertension and metabolic syndrome - Google Patents

Method for correcting impaired purine metabolism in patients with arterial hypertension and metabolic syndrome

Info

Publication number
UA88508U
UA88508U UAU201308366U UAU201308366U UA88508U UA 88508 U UA88508 U UA 88508U UA U201308366 U UAU201308366 U UA U201308366U UA U201308366 U UAU201308366 U UA U201308366U UA 88508 U UA88508 U UA 88508U
Authority
UA
Ukraine
Prior art keywords
huds
prescribed
purine metabolism
content
concentration
Prior art date
Application number
UAU201308366U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Сергій Миколайович Коваль
Ірина Олександрівна Снігурська
Дмитро Кирилович Милославський
Вадим В'ячеславович Божко
Марина Юріївна Пенькова
Ольга Владиславівна Мисниченко
Олена Миколаївна Щенявська
Original Assignee
Державна Установа "Національний Інститут Терапії Ім. Л.Т. Малої Намн України"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Державна Установа "Національний Інститут Терапії Ім. Л.Т. Малої Намн України" filed Critical Державна Установа "Національний Інститут Терапії Ім. Л.Т. Малої Намн України"
Priority to UAU201308366U priority Critical patent/UA88508U/en
Publication of UA88508U publication Critical patent/UA88508U/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A method for correcting the impaired purine metabolism in the patients with arterial hypertension and metabolic syndrome comprises the biochemical examination of the blood serum for measuring the concentration of uric acid (UA). In the setting of the background antihypertensive therapy, hypouricemic drugs (HUDs) are prescribed. In addition, the blood concentrations of C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) are measured. UA content is also determined in the urine. HUDs are prescribed differentially based on the detected type of the purine metabolism. In cases of the impaired purine metabolism associated with hyperuricemia when UA content is above the normal value only in blood serum, HUDs with uricodepressive activity is prescribed, for example Allopurinol at the prophylactic dose. In cases of the impaired purine metabolism associated with combined hyperuricemia and hyperuricosuria when UA content is above the normal value both in blood serum and in urine, the fixed low dose of the combined HUDs with uricodepressive and uricosuric activities is prescribed, for example Allomaron. When CRP concentration is increased at least by 15 % and VEGF concentration is increased at least by 25 %, the treatment is supplemented with the herbal anti-inflammatory drug such as Homvio-Reuman. HUDs are prescribed at the therapeutically effective and safe doses for 12 weeks. When the normalization of proinflammatory and proangiogenic factors is not sufficient, the treatment course for extra 6 weeks is provided.
UAU201308366U 2013-07-03 2013-07-03 Method for correcting impaired purine metabolism in patients with arterial hypertension and metabolic syndrome UA88508U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201308366U UA88508U (en) 2013-07-03 2013-07-03 Method for correcting impaired purine metabolism in patients with arterial hypertension and metabolic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201308366U UA88508U (en) 2013-07-03 2013-07-03 Method for correcting impaired purine metabolism in patients with arterial hypertension and metabolic syndrome

Publications (1)

Publication Number Publication Date
UA88508U true UA88508U (en) 2014-03-25

Family

ID=56267623

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201308366U UA88508U (en) 2013-07-03 2013-07-03 Method for correcting impaired purine metabolism in patients with arterial hypertension and metabolic syndrome

Country Status (1)

Country Link
UA (1) UA88508U (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109452521A (en) * 2018-12-26 2019-03-12 广东养慕特殊医用食品有限公司 A kind of anti-trioxypurine peptide solid beverage, Preparation method and use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109452521A (en) * 2018-12-26 2019-03-12 广东养慕特殊医用食品有限公司 A kind of anti-trioxypurine peptide solid beverage, Preparation method and use
CN109452521B (en) * 2018-12-26 2022-05-17 广东养慕特殊医用食品有限公司 Auxiliary uric acid peptide reducing solid beverage, preparation method and application

Similar Documents

Publication Publication Date Title
Bronicki et al. Multicenter randomized controlled trial of inhaled nitric oxide for pediatric acute respiratory distress syndrome
WO2012174102A3 (en) Methods and apparatus for guiding medical care based on detected gastric function
NZ601111A (en) Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
Balestra et al. Hypoxic and hyperoxic breathing as a complement to low-intensity physical exercise programs: A proof-of-principle study
RU2016147122A (en) APPLICATION OF SERELAXIN TO REDUCE GDF-15
WO2014072823A3 (en) Device for blood glucose level determination
UA88508U (en) Method for correcting impaired purine metabolism in patients with arterial hypertension and metabolic syndrome
WO2014049438A3 (en) Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof
Nee et al. Elimination of glutamate using CRRT for 72 h in patients with post-cardiac arrest syndrome: A randomized clinical pilot trial
de Godoy et al. Diagnostic criteria and clinical evolution of systemic lymphedema caused by obesity: bioimpedance analysis
Shu et al. Serum adipokine levels in renal transplant recipients
Zhou et al. Traditional Chinese medicine.
Hsieh et al. Horticultural therapy in chronic schizophrenia: a pilot study
Vitchuk et al. Effect of hypovitaminosis D on the activity of chronic spontaneous urticaria
Ivo et al. Correction to: Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy
Kim et al. Suppression of Monosodium Urate-induced NLRP3 Inflammasome Activation by Garlic-derived Sulfur-containing Phytochemicals is Associated with Blocking ROS Generation in RAW 264.7 Macrophages
Marzany et al. Impact of Night Sleep Deprivation on Oxidative Stress and Blood Pressure in Adult Volunteers
Wu et al. Anti-proliferative effectiveness of lercanidipine and its mechanism of action (Experimental study)
Gucuk et al. Spironolactone does not alter cystatin C levels in mildly symptomatic systolic heart failure patients
Rief Venous thromboembolism: case report
Nagase Everolimus/temsirolimus
Park et al. Effects Of 4-Phenyl Butyric Acid, A Chemical Chaperone, On Acute Lung Injury
UA112621U (en) METHOD OF CORRECTION OF ENDOTHELY DYSFUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES
Shum et al. Glycaemic control and clinical outcomes in Chinese institutionalised older adults
梁有峰 et al. Correlation of Ambulatory Arterial Stiffness Index with Left Ventricular Diastolic Function in Patients with Essential Hypertension